CRBP - コ―バス・ファ―マシュ―ティカルズ (Corbus Pharmaceuticals Holdings Inc.) コ―バス・ファ―マシュ―ティカルズ

 CRBPのチャート


 CRBPの企業情報

symbol CRBP
会社名 Corbus Pharmaceuticals Holdings Inc (コ―バス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コールバス・ファーマシューティカルズ・ホールディングス(Corbus Pharmaceuticals Holdings Inc.)は臨床段階の製薬会社である。同社は希少・慢性・深刻炎症性及び線維性疾患を治療するための治療薬の開発・商品化に焦点を当てる。同社は希少な生命を脅かす炎症性線維症疾患の治療薬の開発・商品化を通じて事業を運営する。同社の製品であるlenabasumは慢性炎症を解消し、線維化過程を止めるように設計された合成経口エンドカンナビノイド模倣薬である。lenabasumは内因性経路を活性化することによって炎症を解消し、線維化を停止させるように作用する専門化されたプロ解消脂質メディエーター(SPM)の生産を促進する。同社は全身性硬化症、嚢胞性線維症、びまん性皮膚疾患、皮膚優性皮膚筋炎及び全身性エリテマトーデス(SLE)の4つの疾患を治療するためのlenabasumを開発する。   コ―バス・ファ―マシュ―ティカルズは炎症性線維症の治療薬の開発と商品化に焦点を置く米国のバイオ医薬品会社。第2相臨床試験を行う「リスナブ」は嚢胞性線維症と硬皮症の治療用の経口抗炎症剤。「リスナブ」はカンナビノイド受容体(CB2)を活性化し、抗炎性物質の放出を促進するとともに、炎症性物質の放出とサイトカインの分泌を抑制。   Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
本社所在地 500 River Ridge Drive Norwood MA 02062 USA
代表者氏名 Mark A. Tepper マークA.テッパー
代表者役職名 President Chief Scientific Officer
電話番号 +1 617-963-0103
設立年月日
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 47人
url www.corbuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/crbp
adr_tso
EBITDA EBITDA(百万ドル) -41.67992
終値(lastsale) 6.79
時価総額(marketcap) 388429351.1
時価総額 時価総額(百万ドル) 396.43820
売上高 売上高(百万ドル) 2.60040
企業価値(EV) 企業価値(EV)(百万ドル) 331.84536
当期純利益 当期純利益(百万ドル) -41.42403
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Corbus Pharmaceuticals Holdings Inc revenues increased 10% to $1.8M. Net loss increased 61% to $23.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 65% to $20M (expense) General and administrative increase of 42% to $6M (expense).

 CRBPのテクニカル分析


 CRBPのニュース

   Corbus Pharma plans workforce reduction by 54% to advance clinical programs (NASDAQ:CRBP)  2020/10/08 13:07:35 Seeking Alpha
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) announces restructuring by reduction its workforce by 54% to reallocate capital to certain clinical and precl
   The Daily Biotech Pulse: Bristol-Myers Squibb's Lung Cancer Readout, Positive News From Masimo, Integra Lifesciences  2020/10/07 11:30:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Inspire Medical Systems Inc (NYSE: INSP ) InVitae Corp (NYSE: NVTA ) Kura Oncology Inc (NASDAQ: KURA ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Inc (NASDAQ: PRLD ) ProPhase Labs Inc (NASDAQ: PRPH ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 6) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) (reacted to negative results for a mid-stage study of lenabasum in cystic fibrosis patients) Dyne Therapeutics Inc (NASDAQ: DYN ) Outset Medical Inc (NASDAQ: OM ) Teligent Inc (NASDAQ: TLGT ) Stocks In Focus Integra LifeSciences' Preliminary Q3 Revenues Exceed Estimate Medtech company Integra Lifesciences Holdings Corp (NASDAQ: IART ) preannounced third-quarter results, expecting revenues of $368 million to $370 million, down about 2.7%, but exceeding the company's guidance provided at …
   Cannabis Stock Gainers And Losers From September 29, 2020  2020/09/29 21:09:24 Benzinga
GAINERS: 48North Cannabis (PINK: NCNNF ) shares closed up 27.27% at $0.14 Corbus Pharmaceuticals (NASDAQ: CRBP ) shares closed up 20.12% at $1.97 GrowGeneration (NASDAQ: GRWG ) shares closed up 9.13% at $16.02 Aleafia Health (OTCQX: ALEAF ) shares closed up 7.71% at $0.37 CV Sciences (OTCQB: CVSI ) shares closed up 7.57% at $0.54 Marrone Bio Innovations (NASDAQ: MBII ) shares closed up 6.78% at $1.26 Item 9 Labs (OTCQX: INLB ) shares closed up 1.33% at $6.4 BioHarvest Sciences (OTC: CNVCF) shares closed up … Full story available on Benzinga.com
   Cannabis Stock Gainers And Losers From September 9, 2020  2020/09/09 22:10:36 Benzinga
Gainers: AusCann Group Holdings (OTC: ACNNF ) shares closed up 24.11% at $0.12 Heritage Cannabis Holding (OTC: HERTF ) shares closed up 18.04% at $0.08 NexTech AR Solns (OTC: NEXCF ) shares closed up 13.42% at $4.09 Cann Gr (OTC: CNGGF ) shares closed up 10.34% at $0.32 Corbus Pharmaceuticals (NASDAQ: CRBP ) shares closed up 9.42% at $2.44 Emerald Health (OTC: EMHTF ) shares closed up 8.74% at $0.17 Bloom Energy (NYSE: BE ) … Full story available on Benzinga.com
   The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment  2020/09/09 11:23:14 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Akouos Inc (NASDAQ: AKUS ) Albireo Pharma Inc (NASDAQ: ALB )(announced positive Phase 3 results for odevixibat in a liver disorder called progressive familial intrahepatic cholestasis) Castle Biosciences Inc (NASDAQ: CSTL ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Kura Oncology Inc (NASDAQ: KURA ) Merit Medical Systems, Inc. (NASDAQ: MMSI )(announced sale of manufacturing equipment and associated assets used in its hypotube manufacturing business) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 8) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AEterna Zentaris Inc. (NASDAQ: AEZS )(announced the presentation of data from pediatric study of macimorelin for childhood-onset growth hormone deficiency) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP )( reacted to a negative data readout) Immatics NV (NASDAQ: IMTX ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Legend Biotech Corp (NASDAQ: LEGN ) Regulus Therapeutics Inc (NASDAQ: RGLS ) Royalty Pharma plc (NASDAQ: RPRX ) Second Sight Medical Products Inc (NASDAQ: EYES ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus AstraZeneca Halts Coronavirus Vaccine Study to Allow For Safety Review Following an Unexplained Illness AstraZeneca plc (NYSE: AZN ) shares are under pressure after the company said in a statement to STATNews it has voluntarily paused the study of the coronavirus vaccine candidate it is jointly developing with the Oxford University in order to allow review of safety data by an independent committee.
   Corbus Pharmaceuticals secures debt funding of $50M (NASDAQ:CRBP)  2020/07/29 13:15:12 Seeking Alpha
Corbus Pharmaceuticals (NASDAQ:CRBP) +6%, after the company has announced debt financing facility with K2 HealthVentures of $50M. The company received the
   Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital | MarketScreener  2020/07/29 12:06:01 MarketScreener
Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per shareReceived $20 million first tranche from $50 million debt facility with K2 HealthVentures Cash on… | July 29, 2020
   Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital  2020/07/29 12:05:00 GlobeNewswire
Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per shareReceived $20 million first tranche from $50 million debt…
   Corbus Pharmaceuticals Is an Example of How I'm Playing an Uncertain Market  2020/07/24 12:52:48 The Street RealMoney
CRBP has topline Phase 3 data for its primary compound Lenabasum for Systemic Sclerosis due out this summer….AMZN
   Corbus Pharma is nearing the readout of a pivotal drug study  2020/07/17 08:40:31 STAT News
Here's what you need to know about the Corbus Pharmaceuticals drug, the study design, and the expectations for the readout.
   Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors  2020/07/08 12:05:00 GlobeNewswire
Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several…
   The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts  2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.
   Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress  2020/06/29 12:05:00 GlobeNewswire
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two…
   Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis  2020/06/22 12:05:00 GlobeNewswire
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR…
   Cannabis Stock Gainers And Losers From June 17, 2020  2020/06/17 21:08:17 Benzinga Feeds
Gainers AusCann Group Holdings (OTC: ACNNF ) shares closed up 9.17% at $0.1 Heritage Cannabis Holding (OTC: HERTF ) shares closed up 7.56% at $0.10 Delta 9 Cannabis (OTC: VRNDF ) shares closed up 5.2% at $0.40 High Tide (OTC: HITIF ) shares closed up 5.2% at $0.14 Corbus Pharmaceuticals (NASDAQ: Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コ―バス・ファ―マシュ―ティカルズ CRBP Corbus Pharmaceuticals Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)